Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
NCT01813136Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2013
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in differentiated thyroid carcinoma (DTC), sponsored by Centre Léon Bérard. Started Mar 2013; status: completed.
02
Drugs
pazopanib
03
Conditions
differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT01813136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813136.